title: Topical difluprednate for the treatment of Harada's disease.
abstract: OBJECTIVE
  To describe the use of topical difluprednate for treatment of patients who presented with Harada's disease.
  
  
  METHODS
  Retrospective case series of patients managed with topical difluprednate alone at the onset of the diagnosis. The patients were followed with optical coherence tomography (OCT) and fluorescein angiography.
  
  
  RESULTS
  In our three cases, complete resolution of the exudative detachments with improvement in visual acuity was achieved in each case. Central macular thickness was reduced by a mean of 365±222 μm. Initial loading dose was one drop every hour while awake, followed by a variable tapering regimen. Leakage on fluorescein angiography and exudative detachments on OCT both responded to treatment with difluprednate. In two of the three cases, the patients recovered vision to 20/20, and the third case recovered to 20/25. Steroid-induced glaucoma was observed and managed with one to two glaucoma drops as needed.
  
  
  CONCLUSIONS
  Difluprednate is effective for managing ocular manifestations of Harada's disease. Further studies of this drug for the management of noninfectious posterior uveitis are warranted.
authors: Retina Macula Institute, Torrance, CA, USA.
authors: Spencer M
authors: SM
authors: Onishi
authors: Retina Macula Institute, Torrance, CA, USA.
authors: Masumi G
authors: MG
authors: Asahi
authors: Retina Macula Institute, Torrance, CA, USA.
authors: Calvin
authors: C
authors: Chou
authors: Retina Macula Institute, Torrance, CA, USA.
authors: Ron P
authors: RP
authors: Gallemore
keywords: noninfectious posterior uveitis; serous retinal detachment; steroid
references: Am J Ophthalmol. 2001 May;131(5):647-52
references: 11336942
references: J Ocul Pharmacol Ther. 2011 Feb;27(1):43-9
references: 21118027
references: Arch Ophthalmol. 1963 Oct;70:482-91
references: 14078870
references: Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1178-84
references: 12601047
references: Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):805-10
references: 20180131
references: Invest Ophthalmol Vis Sci. 2014 May 06;55(5):2993-3002
references: 24677110
references: Clin Ophthalmol. 2011;5:811-6
references: 21750615
references: Ophthalmology. 1995 Jul;102(7):1012-5
references: 9121744
references: Int Ophthalmol Clin. 2006 Spring;46(2):111-22
references: 16770158
references: J Ocul Pharmacol Ther. 2010 Oct;26(5):475-83
references: 20809807
references: Clin Immunol. 2011 May;139(2):177-84
references: 21334264
references: Clin Ophthalmol. 2009;3:381-90
references: 19668594
references: Ophthalmology. 1990 Sep;97(9):1137-42
references: 2234843
references: Int J Pharm. 2005 Sep 14;301(1-2):121-8
references: 16023810